Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Hu XE, Yang P, Chen S, Wei G, et al. Breast Cancer Res 2023;25:34.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hu XE, Yang P, Chen S, Wei G, et al. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Breast Cancer Res 2023;25:34.
PMID: 36998014